Development Of An Extended Release Oral Formulation Of Milrinone For Patients With Advanced Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$467,083.00
Summary
Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with indu ....Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with industry as a means to clinical translation.Read moreRead less
Mechanisms Underlying The Contribution Of Uremic Toxins To Cardiorenal Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$413,533.00
Summary
Cardiorenal syndrome (CRS) is an umbrella term that defines disorders of the heart and kidneys whereby “acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other”. We have demonstrated a significant association between heart and kidney fibrosis (scarring) and levels of a uremic toxin called indoxyl sulphate (IS), in relevant animal models and that blockade of production of this toxin reduces cardiac fibrosis. This project aims to explore this association.
Novel Therapy For Heart Failure With Preserved Ejection Fraction
Funder
National Health and Medical Research Council
Funding Amount
$1,068,984.00
Summary
Heart failure is a major cardiovascular problem. Up to half of the patients have a specific problem with heart muscle relaxation. There is no effective therapy for this type of heart failure. We will investigate the effects of new treatment approach using a range of experimental and clinical methods. If successful the treatment could move quickly into clinical practice.
Heart failure (HF) describes where the heart cannot pump adequately to meet the bodyÍs needs. Mortality remains high; therefore, there is an urgent need for new treatment approaches. The present grant aims to: (1) evaluate treatments for patients at high-risk for future development of HF (2) examine the ability to safely withdraw unnecessary HF drugs (3) focus on the effect of HF on the kidney via novel treatment strategies (4) examine the emerging role of cancer drugs in development of HF.
A Study Of The Plaque-modifying Actions Of Colchicine In Stable And Unstable Atherosclerosis: From Mouse Models To Clinical Imaging.
Funder
National Health and Medical Research Council
Funding Amount
$1,198,460.00
Summary
Inflammation causes the plaques in arteries that cause heart attacks and strokes. There is major interest in developing drugs that reduce this inflammation for patients with heart disease. We are studying the effects of colchicine, an anti-inflammatory drug used to treat the joint disease, gout, in order to see whether it also prevents the build up of plaques and their progression to heart attacks and strokes.
LoDoCo2 Low Dose Colchicine For Secondary Prevention In Stable Coronary Heart Disease (the LoDoCo2 Trial)
Funder
National Health and Medical Research Council
Funding Amount
$2,399,884.00
Summary
We are conducting clinical trial in several thousand patients to assess the effect of a common, inexpensive and readily available anti-inflammatory drug, colchicine, on heart attack. Colchicine is widely used for treating gout, which is due to inflammation in joints. Since inflammation is an important process makes a cholesterol plaque unstable and can lead to coronary thrombosis and heart attack, we are hypothesising that cholesterol can limit this process.
The Role Of Angiotensin Converting Enzyme 2 In Limiting Complications Of Aortic Aneurysm.
Funder
National Health and Medical Research Council
Funding Amount
$684,989.00
Summary
Artery weakening or aneurysm is an important cause of mortality in older adults. Currently there are only surgical therapies for artery weakening. In this project the role of a protein which may inhibit artery weakening is investigated. In this project we assess if targeting this protein could limit artery weakening using pre-clinical models.
Mapping In Atrial Fibrillation: A 3-dimensional Electrophysiological Evaluation Of The Electro-pathological Substrate
Funder
National Health and Medical Research Council
Funding Amount
$416,961.00
Summary
Atrial fibrillation is the most frequently encountered heart rhythm disorder. However, mechanisms underlying the progressive nature of this disease remain poorly understood. This study aims to characterize the 3-D electrical dissociation and its relation to pathological changes in conditions predisposing to atrial fibrillation. This knowledge will facilitate the development of individualized, substrate-oriented pharmacological treatment and targeted therapeutic procedures for atrial fibrillation ....Atrial fibrillation is the most frequently encountered heart rhythm disorder. However, mechanisms underlying the progressive nature of this disease remain poorly understood. This study aims to characterize the 3-D electrical dissociation and its relation to pathological changes in conditions predisposing to atrial fibrillation. This knowledge will facilitate the development of individualized, substrate-oriented pharmacological treatment and targeted therapeutic procedures for atrial fibrillation.Read moreRead less
Delivering Nanoparticles To Prevent Rupture Of Unstable Arterial Plaques
Funder
National Health and Medical Research Council
Funding Amount
$613,652.00
Summary
The aim of this project is to develop an immune-mediated ‘smart bomb’ concept of drug delivery into atherosclerotic plaques for the prevention of plaque rupture. An overwhelming majority of fatal heart attacks and sudden death all over the world result from plaque rupture; making this research highly important in finding a bio-technologically advanced way of preventing heart attacks and sudden death in patients with coronary artery disease.
Developing Functionalised Microbubbles For Molecular Ultrasound Imaging And Targeted Delivery Of Drugs And MicroRNA Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$677,229.00
Summary
We aim to develop gas-filled microbubbles that are directed to markers of thrombosis and inflammation and will allow visualisation of blood clots and early inflammatory reactions via ultrasound. This will allow early and timely treatment. We will systematically test for the best method of microbubble coating with recombinant antibodies in various animal models of thrombosis and inflammation. In addition, we plan to load microbubbles with drugs and target these to areas where they are needed.